INTESTINE INFLAMMATION

Evidence for the presence of functional protease activated receptor 4 (PAR₄) in the rat colon

F Mulè, R Pizzuti, A Capparelli, N Vergnolle

Gut 2004;53:229–234

See end of article for authors' affiliations

Correspondence to: Professor F Mulè, Dipartimento di Biologia cellulare e dello Sviluppo, Laboratorio di Fisiologia generale, Università di Palermo, Viale delle Scienze, 90128 Palermo, Italy; fmulè@unipa.it

Accepted for publication 2 September 2003

Background and aims: Protease activated receptors (PARs) have been postulated to play a role during intestinal inflammation. The presence and role played by PAR₄ in gastrointestinal functions have not been fully clarified. The aims of this study were: (i) to examine expression of PAR₄ in rat proximal colon; (ii) to determine the mechanical effects induced by PAR₄ activation in longitudinal muscle; and (iii) to characterise the underlying mechanisms.

Methods: PAR₄ expression was determined by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. Mechanical activity was recorded as changes in isometric tension.

Results: A PCR product corresponding to the predicted size of the PAR₄ signal was amplified from RNA prepared from the colon of rats, showing the presence of PAR₄ in those tissues. Immunohistochemistry revealed that PAR₄ protein was expressed on epithelial surfaces and submucosa. PAR₄ activating peptides, GYPGKF-NH₂ and AYPGKG-NH₂, produced concentration dependent contractile effects on longitudinal muscle. Tetrodotoxin (TTX) or atropine significantly reduced the contractile responses to AYPGKG-NH₂, and atropine after TTX did not cause any further reduction. NK₁ receptor antagonist, SR140333, or NK₂ receptor antagonist, SR48968, alone or in combination, produced a reduction in PAR₄ induced contractile effect, and when coadministered with TTX abolished it. Capsaicin markedly reduced the contractions evoked by AYPGKG-NH₂.

Conclusions: The present results suggest that PAR₄ is functionally expressed in rat colon and its activation induces contraction of the longitudinal muscle both through TTX sensitive release of acetylcholine and release of tachykinins, probably from sensory nerves. These actions may contribute to motility disturbances during intestinal trauma and inflammation.

In addition to their established proteolytic roles, proteases such as trypsin, thrombin, or cathepsin G may also act as cell signalling molecules via protease activated receptors (PARs). This family of seven transmembrane G protein coupled receptors currently includes four receptor subtypes (PAR₁, PAR₂, PAR₃, PAR₄). PAR₁, PAR₃, and PAR₄, but not PAR₂, are activated by thrombin, whereas trypsin can activate PAR₂ and PAR₄.^{1,2} PAR₄ can also be activated by the neutrophil granule protease cathepsin G.³ Activation of PARs is initiated by proteolytic cleavage of their extracellular N terminal domain resulting in the unmasking of an extracellular N terminal sequence that acts as a tethered receptor activating ligand. PAR₁, PAR₂, and PAR₄ can also be activated by exogenously applied short synthetic peptides, based on the sequences of their tethered ligands.

Numerous studies have been performed to clarify the role of PARs in the physiology and pathophysiology of the gastrointestinal tract as these tissues, more than others, are exposed to proteinases and PARs are highly expressed throughout the gastrointestinal tract.⁴ However, most of the studies concerned the functions of PAR₁ and PAR₂. PAR₁ and PAR₂ most likely play a role during inflammation, allergy, and/or haemorrhage where thrombin and/or mast cell tryptase become available as endogenous agonists. PAR₂ appears to be involved in exocrine secretion^{5,6} and in intestinal ion transport.⁷ PAR₁ and PAR₂ modulate smooth muscle motility⁸ and their activation can induce relaxant, contractile, or biphasic responses.^{9–20} Although northern blot analysis has shown that mRNA for PAR₄ is present in human small and large intestine,²¹ the cell types that express PAR₄ are still unknown and the physiological role played by PAR₄ in the gastrointestinal tract has to be yet fully elucidated. Hollenberg and colleagues¹² have reported contractile effects

on the longitudinal muscle of rat stomach due to activation of PAR₄ by the receptor activating peptide, GYPGQV-NH₂, and lack of cross reactivity with PAR₁ and PAR₂. In addition, in rat oesophageal muscularis mucosae²² and isolated airways,²³ PAR₄ induces relaxation, a function opposed to PAR₁. In contrast, PAR₄ appears to mimic the actions of PAR₁ in the murine airway smooth muscle.²⁴

The present study was designed to investigate whether PAR₄ is present in rat colon and if it affects gut motor functions. The purposes were to: (i) examine expression of PAR₄ in rat proximal colon; (ii) determine the mechanical effects induced by PAR₄ activation in longitudinal smooth muscle; and (iii) characterise the underlying mechanisms. Specifically, the possible involvement of neurogenic mechanisms and the relative contribution of different neurotransmitters were analysed.

METHODS

Animals

Male Wistar rats weighing 250–300 g were obtained from Morini (Italy) and from Charles River Laboratories (Quebec, Canada). All animals were housed in temperature controlled rooms and had free access to food and water. Local animal care committees approved all experimental protocols. Rats were sacrificed by cervical dislocation, and tissues were immediately removed for analysis.

Abbreviations: PARs, protease activated receptors; PBS, phosphate buffer saline; TTX, tetrodotoxin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; EC₅₀, half maximal contractile concentration; RT-PCR, reverse transcription-polymerase chain reaction

RT-PCR

For PAR₄ reverse transcription-polymerase chain reaction (RT-PCR), total RNA from rat colonic tissues was isolated using the Trizol method (Gibco, Canada). RNA (2 µg) was reverse transcribed and DNA was amplified according to the following cycle conditions: dissociation of nucleic strands at 94°C for one minute, annealing at 55°C for 30 seconds, and extension for one minute at 72°C. The primer sequences for rat PAR₄ were 5'-GGA AGT CTT GAG AGA AAG GCA A and 3'-GAA CCA AGA GGC ATC ACC TAT C, and for glyceraldehyde-3-phosphate dehydrogenase (GADPH) 5'-CGG AGT CAA CGG ATT TGG TCG TAT and 3'-AGC CTT CTC CAT GGT GGT GAA GAC. Twenty seven cycles were performed for PAR₄ and 23 cycles for GADPH. PCR products were then separated on a 1% agarose gel with ethidium bromide and the gel was scanned under UV light.

Immunohistochemistry

Rat colon tissues were harvested and fixed in Zamboni's buffer overnight. Tissues were then washed three times in phosphate buffer saline (PBS) and placed in 20% sucrose with PBS. Tissues were embedded in OCT and frozen sections (10 µm) were placed on "superfrost plus" slides. Tissue sections were washed with PBS alone and then incubated for one hour at room temperature with PBS containing 10% donkey serum. Sections were then incubated with primary antibody (affinity purified goat polyclonal anti-PAR₄ antibody; Santa Cruz Biotechnology, California, USA; 1/100 dilution) in PBS with 10% donkey serum overnight at 4°C. In control experiments, the anti-PAR₄ antibody was pre-incubated (for 24–48 hours at 4°C with 1 or 10 µM of) with the blocking peptide used for immunisation (peptide mapping the C terminal domain of mouse PAR₄; Santa Cruz Biotechnology). Slides were washed in PBS and incubated with secondary antibody (Cy3 conjugated AffiniPure donkey antgoat, 1/500 dilution in PBS plus 1.5% donkey serum) for one hour at room temperature. Tissue sections were then covered with Fluorsave reagent and examined using a Olympus IX50/FLA fluorescent microscope equipped with a coolsnap-fx camera.

Mechanical recording

Rat colon was removed distally to the caecum. The colonic lumen was cleaned with Krebs solution and segments of approximately 2 cm in length were cut. The preparation was then placed in a continuously perfused organ bath containing 5 ml of gassed (95% O₂ and 5% CO₂) and heated (37°C) Krebs solution with the following composition (mM): NaCl 119; KCl 4.5; MgSO₄ 2.5; NaHCO₃ 25; KH₂PO₄ 1.2; CaCl₂ 2.5; and glucose 11.1. Preparations were then tied with silk thread to an isometric force transducer (DY2; Ugo Basile, Comerio, Varese, Italy) for recording of isometric tension of the longitudinal muscle on an ink writer recorder (Gemini; Ugo Basile). Segments were allowed to equilibrate for at least 30 minutes under a 1 g load before starting the experiment.

Experimental protocol

After the equilibration period, the preparation was challenged with carbachol at 10 µM which, in preliminary experiments, was demonstrated to induce a maximal effect. Then, responses of the preparations to cumulative concentrations of GYPGKF-NH₂, the murine synthetic PAR₄ activating peptide, AYPGKG-NH₂, which is reported to be a stronger agonist for PAR₄,²⁵ or YAPGKG-NH₂, the inactive control peptide, were examined. The peptides were added into the bath in volumes of 50 µl after switching off the perfusion to give the concentrations indicated. Each concentration was left in contact with the tissue for two minutes. In preliminary experiments, in order to assess the reproducibility of the

responses, we found that concentration related responses obtained with the first concentration-response curve were not significantly different from the second curve.

The response to PAR₄ activation with AYPGKG-NH₂ was assessed in the absence and presence of the following inhibitors/antagonists: tetrodotoxin (TTX 1 µM), a Na⁺ channel blocker; atropine (1 µM), an antagonist of cholinergic muscarinic receptors; SR140333, a selective antagonist of NK₁ receptors (1 µM); SR48968, a selective antagonist of NK₂ receptors (1 µM); and capsaicin at a concentration of 10 µM, which is reported to cause depletion of tachykinins from sensory nerve fibres.^{26, 27} Some antagonists were coadministered to clarify whether the effectors represented different steps of the same pathway. For each drug, the concentration used was known to be effective in our preparation.^{28, 29} The antagonists were added to the perfusing solution at least 30 minutes before testing the PAR activating peptides, except capsaicin. To prove that TTX treatment was effective, the preparation was stimulated through a pair of platinum ring electrodes.

Data analysis and statistics

Because of spontaneous phasic contractions of the tissues, the contractile response of longitudinal muscle was defined as change in resting tone (the bottom level of the tension oscillations), and was expressed as a percentage of contraction caused by 10 µM carbachol. All data are expressed as means (SEM) where n indicates the number of animals from which intestinal segments were taken. The half maximal contractile concentration (EC₅₀) was calculated from individual experiments by non-linear regression. Differences in peptide induced responses in the absence (control) and presence of inhibitors were analysed by the Student's *t* test or analysis of variance (ANOVA) and Bonferroni's correction, when required. A probability value of less than 0.05 was regarded as significant.

Drugs

The following drugs were used: carbamylcholine chloride (carbachol), capsaicin, tetrodotoxin (TTX) (Sigma, Chemical Corp, St Louis, Missouri, USA), ((S)-N-methyl-N [4-(4-acetyl-amino-4-phenylpiperidino)-2-(3, 4-dichloro-phenyl)-butyl]benzamide (SR48968), (S)-1-[2-[3-(3, 4-dichlorophenyl)-1 (3-isopropoxy-phenylacetyl) piperidin-3yl] ethyl]-4-phenyl-1 azanibicyclo [2.2.2] octane chloride (SR140333) (a kind gift from Sanofi Recherche, Montpellier Cédex, France), [Sar⁹, Met(O₂)¹¹]-SP, [β-Ala⁸]-NKA(4–10) (Calbiochem-Novabiochem AG, Laufelfingen, Switzerland). All drugs were dissolved in distilled water, except for the following: SR48968 and SR140333 dissolved in DMSO, capsaicin dissolved in absolute ethanol, [Sar⁹, Met(O₂)¹¹]-SP dissolved in diluted acetic acid, and [β-Ala⁸]-NKA(4–10) dissolved in diluted ammonia. Working solutions were prepared fresh on the day of the experiment by diluting the stock solutions. Control experiments using the different solvents alone showed that none had effects on the tissue responses studied.

GYPGKF-NH₂, AYPGKG-NH₂, and the inactive control peptide YAPGKF-NH₂ were purchases from the Peptide Synthesis Core Facility at the University of Calgary (Canada), and prepared by standard solid phase synthesis procedures.

RESULTS

PAR₄ expression

A PCR product of a predicted size of 463 bp was amplified from RNA prepared from the colon of rats (lanes 1 and 2; fig 1), showing PAR₄ presence in those tissues. In the absence of PAR₄ primer, only GAPDH amplified product (306 bp) was detected in those tissues (lane 3; fig 1). PAR₄ protein

Figure 1 Detection of protease activated receptor 4 (PAR₄) in rat colon by reverse transcription-polymerase chain reaction. Lanes 1 and 2, colon tissues where PAR₄ and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were amplified; a specific 463 bp fragment corresponds to PAR₄ while GAPDH showed an expected amplified fragment of 306 bp. Lane 3 shows omission of PAR₄ primer.

immunoreactivity was also observed in rat colon (fig 2). PAR₄ expression was prominently localised to the mucosal surface (colonocytes; arrowheads in fig 2A), but staining was also observed in the submucosa (arrows in fig 2A). Staining was abolished by preabsorption of antibody with the receptor fragment used to raise the anti-PAR₄ antibody (fig 2B).

Functional studies

Under the present experimental conditions, rat colon smooth muscle showed spontaneous mechanical activity, consisting in rhythmic phasic changes of isometric tension (from 1 to 2.5 g). The PAR₄ activating peptides, GYPGKF-NH₂ (0.01–10 µM) and AYPGQV-NH₂ (0.01–10 µM), caused a concentration dependent contractile response in the longitudinal muscle of rat colon, consisting of an increase in basal tension with maintenance of the phasic contraction (fig 3). AYPGQV-NH₂ (EC₅₀ = 0.08 (0.06) µM; n = 6) was more potent than GYPGKF-NH₂ (EC₅₀ = 0.3 (0.1) µM; n = 8) but efficacy was similar, both peptides being able to reach approximately 90% of the contraction induced by carbachol (10 µM) at the maximal concentration tested (fig 4). In order to verify the specificity of the response, we applied to the preparations the inactive control peptide YAPGQV-NH₂ (0.01–10 µM) and this had no effect (figs 3, 4).

To clarify the mechanism underlying the contractile effect produced by PAR₄ activation, we evaluated the responses evoked by AYPGQV-NH₂ in the presence of TTX. TTX (1 µM), which per se did not modify spontaneous contractions, significantly reduced the responses induced by the PAR₄

activating peptide, but did not abolish them, indicating partial involvement of neural mechanism (fig 5A).

As tachykinins and acetylcholine are among the major excitatory neurotransmitters to intestinal smooth muscle, we evaluated if these mediators could be involved in the PAR₄ agonist induced contractile response. Therefore, we tested the effects of their antagonists on responses evoked by PAR₄ activation both in the absence and presence of TTX. Pretreatment of tissues with the muscarinic antagonist atropine (1 µM) significantly decreased the contractile responses induced by AYPGKF-NH₂ (fig 5A). Contractile responses to 10 µM carbachol were absent in these tissues (data not shown). It is interesting that the reduction in the PAR₄ contractile effect induced by atropine was of the same degree as that induced by TTX; furthermore, subsequent addition of atropine (1 µM) after TTX caused no further reduction of the PAR₄ induced contractile effect (fig 5A).

Both NK₁ and NK₂ receptor antagonists, SR140333 (1 µM) and SR48968 (1 µM), respectively, reduced independently the contractile effects induced by PAR₄ activating peptide (fig 5B). The concentration of the NK₁ receptor selective antagonist SR140333 that we used (1 µM) antagonised the contractile response to the NK₁ receptor agonist [SAR⁹, Met(O₂)¹¹]-SP but not to the NK₂ receptor agonist [β-ala⁸]-neurokinin A (4–10). The concentration of the NK₂ receptor selective antagonist SR48968 that we used (1 µM) antagonised the contractile response to the NK₂ receptor agonist [β-ala⁸]-neurokinin A (4–10) but not to the NK₁ receptor agonist [SAR⁹, Met(O₂)¹¹]-SP (data not shown). The suppressive effects of the NK₁ receptor selective antagonist SR140333 (1 µM) were additive to those induced by the NK₂ receptor selective antagonist SR48968 (1 µM) (fig 5B). When both antagonists were coadministered with TTX (1 µM), the contractile effects evoked by PAR₄ activating peptide were abolished (fig 5B).

Lastly, pretreatment of the preparation with capsaicin (10 µM) for 90 minutes significantly reduced the contractile effects induced by PAR₄ activating peptide (fig 6).

DISCUSSION

Possible physiological/pathophysiological roles for PAR₄ in tissues or cells other than platelets are poorly understood, in spite of their wide distribution in varying tissues.^{12 21 30–32} Considering the effects of PAR₄ agonists on smooth muscles, some evidence indicates the PAR₄ is not involved in modulation of the motility of rat duodenum¹⁶ or guinea pig gall bladder.¹⁸ However, Hollenberg and colleagues¹² have reported that PAR₄ agonists induce contraction of gastric longitudinal smooth muscle and nitric oxide dependent

Figure 2 Immunolocalisation of protease activated receptor 4 (PAR₄) in rat colon. In (A), tissues were incubated with an anti-PAR₄ primary antibody and then with a Cy3 conjugated secondary antibody. The control (B) shows incubation of primary anti-PAR₄ antibody with blocking peptide, followed by Cy3 conjugated secondary antibody. m, mucosa, sm, submucosa, cm, circular muscle. Arrowheads shows colonocyte staining, arrows shows submucosa staining. Scale bar, 10 µm.

Figure 3 Representative recordings of the contractile effects induced by the protease activated receptor 4 (PAR₄) activating peptides, GYPGKF-NH₂ and AYPGKF-NH₂, by the inactive control peptide, YAPGKF-NH₂, and by carbachol (CCh 10 μM) on the longitudinal muscle of rat colon. Arrows indicate application of the agonist. W, washout.

relaxation of vascular smooth muscle. It is not yet clear whether PAR₄ activation plays a role similar or opposite to PAR₁. In fact, PAR₄ activation appears to mimic the effects of PAR₁ activation in gastric and airway smooth muscle,^{12, 24} whereas in the rat oesophageal muscularis mucosae, PAR₄ appears to mediate relaxation, in contrast to PAR₁.²²

The present study demonstrates that PAR₄ is present in rat colon and its activation evokes contraction of intestinal longitudinal smooth muscle. Both GYPGKF-NH₂, corresponding to the murine PAR₄ tethered ligand, and AYPGKF-NH₂, reported to be a more potent peptide analogue for PAR₄,²⁵ induced a concentration dependent contractile response. The control inactive peptide YAPGKF-NH₂ had no contractile effect on longitudinal smooth muscle preparations, thus confirming the specificity of action of the two PAR₄ peptide agonists used. AYPGQV-NH₂ was more potent than GYPGKF-NH₂, which is in accordance with data from the literature.²⁵ The effective concentration range of GYPGKF-NH₂ and AYPGQV-NH₂ for induction of the contractile responses was lower than that required for production of contraction in other preparations.¹² One possible explanation for this observation is that in our

Figure 4 Concentration-response curves for the effects evoked by the protease activated receptor 4 (PAR₄) activating peptides, GYPGKF-NH₂ and AYPGKF-NH₂, and the inactive control peptide, YAPGKF-NH₂, on the longitudinal muscle of rat colon. The contractile effects are expressed as a percentage of the contraction to carbachol (CCh 10 μM). Each value is the mean (SEM) of 4–8 experiments.

preparation the PAR₄ activating peptides were not susceptible to rapid protease degradation, or alternatively the high potency of agonist may reflect greater expression of this type

Figure 5 (A) Effects of tetrodotoxin (TTX) and atropine, alone or in combination, on the contractile responses evoked by protease activated receptor 4 (PAR₄) activating peptide, AYPGKF-NH₂, on the longitudinal muscle of rat colon. The contractile responses to AYPGKF-NH₂ were significantly reduced by TTX (1 μM) or atropine (1 μM). The combination of atropine (1 μM) and TTX (1 μM) did not cause any further reduction. (B) Effects of SR140333 and SR48968, alone, in combination, or after treatment with TTX, on the contractile responses evoked by PAR₄ activating peptide, AYPGKF-NH₂, on the longitudinal muscle of rat colon. The contractile responses to AYPGKF-NH₂ were significantly reduced by SR140333 (1 μM), an antagonist of NK₁ receptors, by SR48968 (1 μM), an antagonist of NK₂ receptors, and even more by a combination of SR48968 (1 μM) and SR140333 (1 μM). AYPGKF-NH₂ did not induce any response in the presence of a combination of SR48968 (1 μM), SR140333 (1 μM), and TTX (1 μM). The contractile effects are expressed as a percentage of the contraction to carbachol (CCh 10 μM). Each value is mean (SEM) of five experiments. **p* < 0.05 compared with control value; †*p* > 0.05 compared with TTX or atropine alone; ‡*p* < 0.05 compared with SR140333 and SR48968 alone; §*p* < 0.05 compared with the combination of SR140333 and SR48968.

Figure 6 Concentration-response curves for the effects evoked by the protease activated receptor 4 (PAR₄) activating peptide AYPGKF-NH₂ on the longitudinal muscle of rat colon in the absence or presence of capsaicin. Capsaicin (10 μM) significantly antagonised the contractile response to the PAR₄ agonist. The contractile effects are expressed as a percentage of the contraction to carbachol (CCh 10 μM). Each value is the mean (SEM) of five experiments. **p* < 0.05 compared with control values.

of receptor in the colon than in the stomach, as reported by Xu and colleagues.²¹

However, the contractile effects we demonstrated for PAR₄ agonists in rat colonic smooth muscle preparations suggest a role for this receptor in motility functions of the gut. Whether or not this role is associated with pathophysiological circumstances may depend on the availability of endogenous proteases in the vicinity of the receptor. Which endogenous protease activates PAR₄ in intestinal tissues remains to be established. Both thrombin and trypsin have been reported to activate PAR₄.²¹ In a previous study, we demonstrated that thrombin and trypsin induced contractile effects in rat colonic longitudinal muscle preparations, showing biphasic responses: relaxation followed by contraction for the highest concentrations.¹⁹ These effects were mimicked by PAR₁ and PAR₂ activating peptides, suggesting that thrombin and trypsin could be responsible for endogenous activation of PAR₁ and PAR₂, respectively. However, the present results highlight PAR₄ as another potential effector of both thrombin and trypsin. The similar effects of PAR₁, PAR₂, and PAR₄ could make redundant the effects of thrombin and trypsin in rat intestinal longitudinal muscle as was suggested for platelets and smooth muscles from gastric, vascular, and airway tissues.^{12 24 30 31 33} Recently, the neutrophil granule protease cathepsin G³ has been found to stimulate PAR₄. This adds cathepsin G to the list of potential endogenous activators of PAR₄ in intestinal tissues. Moreover, it links PAR₄ activation in those tissues to the presence of granulocytes, suggesting that inflammatory pathophysiological circumstances, such as inflammatory bowel diseases, may be associated with PAR₄ activation.

We examined the mechanism by which PAR₄ activation induces contractile effects in rat colonic longitudinal muscle by treating the preparation with TTX, a neuronal conduction blocker, to assess the role of neurotransmission in the evoked effect. The finding that the contractile responses to PAR₄ activating peptides were antagonised, although not completely, by TTX, suggests that a neurogenic component is involved in the PAR₄ agonist evoked effect. Previous studies have reported that PAR₁ and PAR₂ are expressed by a large proportion of neurones of the myenteric plexus of the guinea

pig intestine³⁴ and PAR₂ receptors are expressed on cholinergic nerves in porcine ileum.³⁵ However, information on the cellular localisation of PAR₄ in intestinal tissue is lacking. In mouse, PAR₄ expression on peripheral nerves of bladder has been shown.³⁶ We observed immunostaining for PAR₄ in submucosal structures which could be submucosal neurones (fig 2A), but double labelling with a neuronal marker would be necessary to ascertain that PAR₄ is expressed on neurones in the rat colon. We have evaluated if acetylcholine or tachykinins could be responsible for the PAR₄ neurally mediated effect because these chemical mediators are considered the major excitatory neurotransmitters of intestinal smooth muscle. Atropine reduced the contractile response to PAR₄ activation to the same extent as TTX but failed to decrease it further after TTX treatment. This indicates that PAR₄ activation can induce acetylcholine release through an action potential dependent neural mechanism. In addition, NK₁ and NK₂ receptor antagonists, when administered separately or in combination, reduced contraction due to PAR₄ activation, suggesting involvement of these receptors in the effects evoked by AYPGKF-NH₂. The presence of these receptors, which mediate contraction in the rat colon, has been demonstrated previously by histochemical and functional studies.^{26 37 38} On the other hand, the action of both SR140333 and SR48968 has to be considered as specifically linked to occupancy of NK₁ or NK₂ receptors, respectively, as these drugs antagonised exclusively contraction induced by selective agonists of the respective receptors. Because the suppressive effects of NK₁ and NK₂ receptor antagonists were additive to the effect of TTX, it could be hypothesised that PAR₄ activation can induce tachykinin release without the contribution of propagated action potential (TTX resistant release). In fact, TTX may not inhibit release of neurotransmitters following direct stimulation of receptors present in nerve terminals. Therefore, we hypothesise that prejunctional PAR₄ may directly induce the release of tachykinins, which are mostly released by neurones in the gut.²⁶

In addition, capsaicin significantly reduced the response induced by PAR₄ activating peptide. Although capsaicin can cause different effects, such as VR1 receptor desensitisation or blockade of voltage gated calcium channels, it is likely that the effect of 10 μM capsaicin for 90 minutes can be attributed to an inhibitory effect on the release of biologically active substances, such as tachykinins, by sensory nerve fibres.^{26 27} Depletion of tachykinins from sensory nerves could account for the reduction in contractile effect to PAR₄ activation. It has been reported that PAR₂ activation stimulates the release of substance P from terminals of capsaicin sensitive primary sensory neurones, thus causing neurogenic inflammatory responses in peripheral tissue.³⁹ Interestingly, a similar system has also been described for trypsin induced contraction of the guinea pig bronchus, with release of tachykinins from sensory nerves being responsible for the final contractile response.^{40 41} In addition, our recent data have suggested that PAR₁ and PAR₂ activation can induce neural tachykinin release.²⁹

In conclusion, this study has demonstrated for the first time that PAR₄ is functionally expressed in rat colon. It can mediate a contractile response of longitudinal muscle through TTX sensitive release of acetylcholine and through action potential independent release of tachykinins, probably from sensory nerves. This mechanism of action may support a proinflammatory role for PAR₄, which could contribute to motility disturbances observed during intestinal trauma and inflammation.

ACKNOWLEDGEMENTS

This work was supported by a grant from Ministero dell'Università e della Ricerca scientifica, Italy (FM), the Canadian Institute for Health

Research (NV), and the Canadian Association of Gastroenterology (NV).

Authors' affiliations

F Mulè, Dipartimento di Biologia cellulare e dello Sviluppo, Università di Palermo, Palermo, Italy

R Pizzuti, A Capparelli, Dipartimento Farmaco-Biologico, Università della Calabria, Arcavacata di Rende (Cs), Italy

N Vergnolle, Department of Pharmacology and Therapeutics, University of Calgary, AB, Canada

REFERENCES

- Dery O, Corvera CU, Steinhoff M, et al. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. *Am J Physiol* 1998;**274**:C1429–52.
- Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. *Pharmacol Rev* 2001;**53**:245–82.
- Sambrano GR, Huang W, Faruqi T, et al. Cathepsin G activates protease-activated receptor-4 in human platelets. *J Biol Chem* 2000;**275**:6818–23.
- Vergnolle N. Proteinase-activated receptors—novel signals for gastrointestinal pathophysiology. *Aliment Pharmacol Ther* 2000;**14**:257–66.
- Nguyen TD, Moody MW, Steinhoff M, et al. Trypsin activates pancreatic duct epithelial cell ion channels. *J Clin Invest* 1999;**103**:261–9.
- Kawabata A, Nishikawa H, Kuroda R, et al. Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic exocrine secretion in vivo in rats and mice. *Br J Pharmacol* 2000;**129**:1808–14.
- Vergnolle N, Macnaughton WK, Al-Ani B, et al. Proteinase-activated receptor 2 (PAR₂)-activating peptides: identification of a receptor distinct from PAR₂ that regulates intestinal transport. *Proc Natl Acad Sci U S A* 1998;**95**:7766–71.
- Kawabata A, Kuroda R, Nagata N, et al. In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse. *Br J Pharmacol* 2001;**133**:1213–18.
- Al-Ani B, Saifeddine M, Hollenberg MD. Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH₂, in rat vascular and gastric smooth muscle. *Can J Physiol Pharmacol* 1995;**73**:1203–7.
- Saifeddine M, Al-Ani B, Cheng CH, et al. Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. *Br J Pharmacol* 1996;**118**:521–30.
- Corvera CU, Dery O, McConalogue K, et al. Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2. *J Clin Invest* 1997;**100**:1383–93.
- Hollenberg MD, Saifeddine M, Al-Ani B, et al. Proteinase-activated receptor 4 (PAR₄): action of PAR₄-activating peptides in vascular and gastric tissue and lack of cross-reactivity with PAR₁ and PAR₂. *Can J Physiol Pharmacol* 1999;**77**:458–64.
- Hollenberg MD, Saifeddine M, Al-Ani B, et al. Proteinase activated receptor: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides. *Can J Physiol Pharmacol* 1997;**75**:832–41.
- Zheng XL, Renaux B, Hollenberg MD. Parallel contractile signal transduction pathways activated by receptors for thrombin and epidermal growth factor-urogastrone in guinea pig gastric smooth muscle: blockade by inhibitors of mitogen-activated protein kinase-kinase and phosphatidylinositol 3'-kinase. *J Pharmacol Exp Ther* 1998;**285**:325–34.
- Cocks TM, Sozzi V, Moffatt JD, et al. Protease-activated receptors mediate apamin-sensitive relaxation of mouse and guinea pig gastrointestinal smooth muscle. *Gastroenterology* 1999;**116**:586–92.
- Kawabata A, Kuroda R, Nishikawa H, et al. Modulation by protease-activated receptors of the rat duodenal motility in vitro: possible mechanisms underlying the evoked contraction and relaxation. *Br J Pharmacol* 1999;**128**:865–72.
- Kawabata A, Kuroda R, Kuroki N, et al. Characterization of protease-activated receptor-1-mediated contraction and relaxation in the rat duodenal smooth muscle. *Life Sci* 2000;**67**:2521–30.
- Tognetto M, Trevisani M, Maggiore B, et al. Evidence that PAR-1 and PAR-2 mediate prostanoic-dependent contraction in isolated guinea-pig gallbladder. *Br J Pharmacol* 2000;**131**:689–94.
- Mulè F, Baffi MC, Cerra MC. Dual effect mediated by protease-activated receptors on the mechanical activity of rat colon. *Br J Pharmacol* 2002;**136**:367–74.
- Mulè F, Baffi MC, Falzone M, et al. Signal transduction pathways involved in the mechanical responses to the protease-activated receptors in rat colon. *J Pharmacol Exp Ther* 2002;**303**:1–8.
- Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. *Proc Natl Acad Sci U S A* 1998;**95**:6642–6.
- Kawabata A, Kuroda R, Kuroki N, et al. Dual modulation by thrombin of the motility of rat oesophageal muscularis mucosae via two distinct protease-activated receptors (PARs): a novel role for PAR-4 as opposed to PAR-1. *Br J Pharmacol* 2000;**131**:578–84.
- Chow JM, Moffatt JD, Cocks TM. Effect of protease-activated receptor (PAR)-1, -2 and -4-activating peptides, thrombin and trypsin in rat isolated airways. *Br J Pharmacol* 2000;**131**:1584–91.
- Lan RS, Stewart GA, Henry PJ. Modulation of airway smooth muscle tone by protease activated receptor-1, -2, -3 and -4 in trachea isolated from influenza A virus-infected mice. *Br J Pharmacol* 2000;**129**:63–70.
- Faruqi TR, Weiss EJ, Shapiro MJ, et al. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. *J Biol Chem* 2000;**275**:19728–34.
- Maggi CA. Tachykinins and calcitonin gene-related peptide (CGRP) as cotransmitters released from peripheral endings of sensory nerves. *Prog Neurobiol* 1995;**45**:1–98.
- Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. *Pharmacol Rev* 1991;**43**:143–201.
- Mulè F, D'angelo S, Tabacchi G, et al. Involvement of tachykinin NK₂ receptors in the modulation of spontaneous motility in rat proximal colon. *Neurogastroenterol Mot* 2000;**12**:459–66.
- Mulè F, Baffi MC, Capparelli A, et al. Involvement of nitric oxide and tachykinins in the effects induced by protease-activated receptors in rat colon longitudinal muscle. *Br J Pharmacol* 2003;**139**:598–604.
- Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. *Nature* 1998;**394**:690–4.
- Kahn ML, Nakanishi-Matsui M, Shapiro MJ, et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. *J Clin Invest* 1999;**103**:879–87.
- Bretschneider E, Kaufmann R, Braun M, et al. Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. *Br J Pharmacol* 2000;**132**:1441–6.
- Coughlin SR. Protease-activated receptors and platelet function. *Thromb Haemost* 1999;**82**:353–6.
- Corvera CU, Dery O, McConalogue K, et al. Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and -2. *J Physiol* 1999;**517**:741–56.
- Green BT, Bunnett NW, Kulkarni-Narla A, et al. Intestinal type 2 proteinase-activated receptors: expression in opioid-sensitive secretomotor neural circuits that mediate epithelial ion transport. *J Pharmacol Exp Ther* 2000;**295**:410–16.
- D'Andrea MR, Saban MR, Nguyen NB, et al. Expression of protease-activated receptor-1, -2, -3, and -4 in control and experimentally inflamed mouse bladder. *Am J Pathol* 2003;**162**:907–23.
- Grady EF, Baluk P, Böhm S, et al. Characterization of antisera specific to NK1, NK2, and NK3 neurokinin receptors and their utilization to localize receptors in the rat gastrointestinal tract. *J Neurosci* 1996;**16**:6975–86.
- Serio R, Mulè F, Bonvissuto F, et al. Tachykinins mediate noncholinergic excitatory neural responses in the circular muscle of rat proximal colon. *Can J Physiol Pharmacol* 1998;**76**:684–9.
- Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. *Nat Med* 2000;**6**:151–8.
- Carr MJ, Schechter M, Udem BJ. Trypsin-induced, neurokinin-mediated contraction of guinea-pig bronchus. *Am J Resp Crit Care Med* 2000;**162**:1662–7.
- Ricciardolo FL, Steinhoff M, Amadesi S, et al. Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways. *Am J Resp Crit Care Med* 2000;**161**:1672–80.